GE 37468A

Drug Profile

GE 37468A

Latest Information Update: 30 Sep 2005

Price : $50

At a glance

  • Originator Biosearch Italia
  • Class Antibacterials; Peptide antibiotics
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 30 Sep 2005 Vicuron Pharmaceuticals has since been acquired by and merged into Pfizer
  • 21 May 2001 No-Development-Reported for Bacterial infections in Italy (IV)
  • 01 Dec 1994 Preclinical development for Bacterial infections in Italy (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top